1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Multi-centric Castleman's Disease: new trials by email Literature Review of Multi-centric Castleman's Disease trials Research Report on Multi-centric Castleman's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease Siltuximab - Idiopathic Multicentric Castleman's Disease | Phase 2 | Terminated | RECORDATI GROUP | 22 | 2021-03-31 | 2021-04-19 |
siltuximab (1)
RECORDATI GROUP (1)
United States (1)
Chris Keuker, MD (1)